Bio-Path (NASDAQ:BPTH) Given Buy Rating at Roth Mkm

Bio-Path (NASDAQ:BPTH)‘s stock had its “buy” rating reaffirmed by stock analysts at Roth Mkm in a research note issued to investors on Monday, Benzinga reports. They presently have a $20.00 target price on the stock.

Separately, StockNews.com assumed coverage on shares of Bio-Path in a research report on Thursday, May 2nd. They set a “sell” rating for the company.

Bio-Path Stock Performance

Shares of BPTH stock opened at $1.64 on Monday. The business has a 50-day moving average of $2.27 and a 200 day moving average of $5.16. Bio-Path has a 1-year low of $1.61 and a 1-year high of $30.90.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($4.88) earnings per share for the quarter, missing the consensus estimate of ($4.54) by ($0.34). As a group, equities analysts anticipate that Bio-Path will post -5.53 EPS for the current year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.